Bleomycin induced flagellate pigmentation and sclerodermoid change co-existent in a patient of Hodgkin’s lymphoma
Keywords:
Bleomycin, flagellate pigmentation, sclerodermoid changeAbstract
Bleomycin is a chemotherapeutic drug known to cause a variety of cutaneous side-effects. Pigmentary changes are the commonest. We report a case of bleomycin induced flagellate pigmentation and sclerodermoid change co-existent in a patient of Hodgkin’s lymphoma.ÂReferences
Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin N Am. 1986;70:187-209.
Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Int Med. 1981;94:66-74.
Soble AR. Chronic bleomycin-associated Raynaud's phenomenon. Cancer Treatment Reports. 1978;60:570.
Gupta L, Tanwar R K, Khare A, Jain S. Bleomycin induced flagellate pigmentation. Indian J Dermatol Venereol Leprol. 2002;68:158-9.
Duhra P, Ilchyshyn A, Das RN. Bleomycin-induced flagellate erythema. Clin Exp Dermatol. 1991;16:216-7.
Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin. J Rheumatol. 1992;19:294-6.
Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol. 1994;131:700-2.
Cortina P, Garrido JA, Tomas JF et al. 'Flagellate' erythema from bleomycin with histopathological findings suggestive of inflammatory oncotaxis. Dermatologica. 1990;180:106-9.
